Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Amrif
Wageningen*, Gelderland*, Netherlandsamrif.eu ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Amrif is developing RESCAP, a proprietary oral enzyme supplement based on alkaline phosphatase. Preclinical studies in animal models have shown that supplementation with this enzyme can restore gut barrier function and significantly increase lifespan and healthspan. The company targets age-related and chronic inflammatory diseases but has not yet reported human clinical trial results.
- Therapeutic areas
- OtherImmunology
- Modalities
- Enzyme therapy (alkaline phosphatase/AP)
- Industry
- Biotech
Beyond the preview
Go deeper on Amrif.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amrif.